Loading asset research
Autolus Therapeutics plc American Depositary Share
AUTLNasdaq · USD · StocksQuote as of · Exchange session not verified$1.88
-3.83%
Today
AUTL
Loading 1D prices…
Market cap
$500.4M
Volume
1.7M
52w high
$2.5852w low
$1.17Company profile
Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
London, United Kingdom, United States
Employees
752
Fiscal year end
1231
CIK
1730463
Session & valuation
Open$1.98
Previous close$1.96
Day high$1.98
Day low$1.87
30-day avg. volume2.9M
Outstanding shares266.2M
Diluted EPS-$1.08
Latest annual period
P/E (trailing)-1.75
P/E (forward)-3.00
Price / book0.32
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ARTVArtiva Biotherapeutics Inc. Common Stock | $499.7M | $0.00 | — | -$3.43 | -1.82% | Buy |
| ZURAZura Bio Limited Class A Ordinary Shares | $499.3M | $0.00 | — | -$1.06 | -3.16% | Buy |
| ENTXEntera Bio Ltd. Ordinary Shares | $491.7M | $42K | -27235.71% | $0.25 | +1.25% | Buy |
| EIKNEikon Therapeutics Inc. Common Stock | $484.2M | $0.00 | — | -$6.18 | -3.04% | Buy |
| CABACabaletta Bio Inc. Common Stock | $462.9M | $0.00 | — | -$2.10 | -0.18% | Buy |